Lymphocytic Esophagitis Associated With Chronic Severe Psoriasis: A Case Report With Special Reference to Programmed Death-Ligand 1 Expression.

Lymphocytic esophagitis (LE) is a rare type of chronic esophagitis, marked by an increased number of peripapillary intraepithelial lymphocytes (IEL) with little to no presence of intraepithelial granulocytes and intercellular edema. There is currently no established standard for quantifying IEL in the esophageal mucosa. Clinically, LE manifests with a range of symptoms, including difficulty swallowing (dysphagia), indigestion (dyspepsia), nausea, and chest pain.

Quiz CORRECT ANSWER TO THE QUIZ. CHECK YOUR DIAGNOSIS Prostatic paraganglia-hyperplasia - a histological mimic of intraprostatic adipose tissue.

Prostatic paraganglia (PP) can simulate adenocarcinoma's fused gland pattern, and a differential diagnostic panel is developed. Their differential diagnosis with benign prostatic lesions has been largely unreported. Intraprostatic adipose tissue (IPAT) is seen extremely rarely in prostatic specimens, but it must be known, to avoid false positive results for extraprostatic fat carcinomatous invasion in needle biopsy specimens.

Evidence of Programmed Death-Ligand 1 Expression in a Highly Inflammatory Prostate: A Literature Review and Our Experience.

Chronic inflammation (CI), a common finding in the human prostate, is associated with the most frequent socially important prostate diseases: prostatitis, benign prostatic hyperplasia, and prostate adenocarcinoma. Programmed cell death protein 1 (PD-1) and its ligand (PD-L1) expression are induced on the surface of immune and epithelial cells of healthy and tumor tissues in response to various cytokines. Here, we provide a comprehensive review of the PD-1/PD-L1 pathway in the non- and peri-tumoral inflammatory prostate, focusing on the structure and expression of PD-L1 and the diverse biological functions of PD-L1 signaling in health, high-grade CI (National Institutes of Health, category IV prostatitis or histologic prostatitis), and immune-related diseases, including autoimmunity, tumor microenvironmental immunity, and immune privilege.

Strong YKL-40 expression in the invasive tumor front of colorectal cancer-A pilot study.

Тhe poor prognosis of patients initially diagnosed at an advanced stage of colorectal cancer (CRC) and the heterogeneity within the same tumor stage define the need for additional predictive biomarkers. Tumor buds are proposed as a poor prognostic factor for CRC, however, they are still not implemented into routine pathology reporting. In turn, the chitinase-3-like protein 1 (CHI3L1) also known as YKL-40, is regarded as a candidate circulating biomarker and therapeutic target in CRC.